Georgia State University

ScholarWorks @ Georgia State University
Nutrition Faculty Publications

Department of Nutrition

2013

The “one-two punch” of isoprenoids to inflammation
Huanbiao Mo
Georgia State University, hmo@gsu.edu

Follow this and additional works at: https://scholarworks.gsu.edu/nutrition_facpub
Part of the Nutrition Commons

Recommended Citation
Mo H (2013) The “One-Two Punch” of Isoprenoids to Inflammation. J Nutr Disorders Ther 3: e109

This Editorial is brought to you for free and open access by the Department of Nutrition at ScholarWorks @ Georgia
State University. It has been accepted for inclusion in Nutrition Faculty Publications by an authorized administrator
of ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.

Nutritional Disorders & Therapy
Editorial

Mo, J Nutr Disorders Ther 2013, 3:3
http://dx.doi.org/10.4172/2161-0509.1000e109

Open Access

The “One-Two Punch” of Isoprenoids to Inflammation
Huanbiao Mo*
Department of Nutrition and Food Sciences, Texas Woman’s University, Denton, TX 76204, USA

A large body of evidence from recent studies has shown that
tocotrienols, the vitamin E molecules with an unsaturated farnesyl side
chain, have potential in the prevention and/or treatment of cancer,
metabolic syndrome, obesity, diabetes, osteoporosis, and neurodegeneration [1]. These activities of tocotrienols may converge on the
emerging finding that tocotrienols suppress the activation of nuclear
factor kappa B (NFκB), a major mediator in chronic inflammation
that is gaining recognition as one of the main mechanisms underlying
these chronic diseases. Tocotrienol-mediated inhibition of NFκB
DNA binding activity or suppression of tumor necrosis factor α- and
lipopolysaccharide-induced NFκB expression has been demonstrated
in human breast cancer cells [2,3], colon carcinoma cells [4], malignant
melanoma cells [5], pancreatic cancer cells [6], gastric cancer cells [7],
metastatic oral cancer cells [8], adipocytes [9], and macrophages [10].
Moreover, the in vitro NFκB-suppressive activity of tocotrienols was
borne out in gastric cancer [7] and pancreatic cancer [11] in nude mice.
Readers are referred to recent reviews [12-14] for more details on the
anti-inflammatory activity of tocotrienols.
A closer examination of the NFκB-suppressive activity of
tocotrienols revealed a more fundamental biological activity of
tocotrienols; NFκB suppression may be a secondary effect of tocotrienolmediated down-regulation of another biochemical pathway that is
ubiquitous in virtually all eukaryotic cells: the mevalonate pathway [15].
The mevalonate pathway operating in sterologenic tissues provides – in
addition to cholesterol that is an essential component of cell membrane
and a precursor to vitamin D, bile acids and steroid hormones-essential
intermediates including farnesyl- and geranylgeranyl- pyrophosphates
for the post-translational prenylation of growth-related proteins such
as Ras and nuclear lamins and N-linked glycosylation of insulin-like
growth factor receptor I. Most importantly, prenylated Ras activates
NFκB [16].
The rate-limiting enzyme in the mevalonate pathway, 3-hydroxy3-methylglutaryl coenzyme A (HMG CoA) reductase, is under a
multivalent regulation consisting of sterol-mediated transcriptional
feedback inhibition and a non-sterol-mediated post-transcriptional
down-regulation. Tocotrienols suppress HMG CoA reductase at both
transcriptional and post-transcriptional levels [17] and consequently,
deplete the pool of prenyl pyrophosphates required for the prenylation
of Ras and inactivate NFκB. Ahn et al. showed that tocotrienol-mediated
ablation of NFκB activity was reversed by supplemental mevalonate,
the product of the reaction catalyzed by HMG CoA reductase [15],
establishing mevalonate deprivation as the primary cause for NFκB
inactivation.
Tocotrienols may represent a broad class of isoprenoids
encompassing approximately 23,000 mevalonate-derived end-products
of plant secondary metabolism. Isoprenoids can be classified based on
the number of isoprene units they contain, e.g. monoterpene (2x),
sesquiterpene (3x), diterpene (4x), triterpene (6x) and polyterpene
(Nx) [18]. In addition to these “pure” isoprenoids, the “mixed”
isoprenoids including the tocotrienols have non-mevalonate-derived
moieties. Assorted isoprenoids have a wide spectrum of functions in
the plant kingdom, ranging from growth regulation to insect attraction,
pollination assistance, and pest resistance. Fruits, vegetables and grains
are the main sources of dietary isoprenoids.
The HMG CoA reductase-suppressive activity is extensively
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observed among isoprenoids [19]. It is therefore no coincidence that
a number of isoprenoids under investigation also suppress NFκB
activity. The monoterpene limonene inhibited NFκB activation in
human HL60 clone 15 leukemia cells [20] while an oxidative product
of limonene, perillyl alcohol, suppressed NFκB in B-lymphoma cells
[21]. A third monoterpene, geraniol, suppressed 12-O-tetradecanoyl
phorbol-13-acetate (TPA)-induced inflammatory responses and upregulation of NFκB and COX-2 in mice [22]. A sesquiterpene β-ionone
inhibited tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL)-induced NFκB activation in human HepB3 and HepG2
hepatocellular carcinoma cells [23]. Various sesquiterpene lactones
blocked NFκB activity [24]. Diterpene coronarin D suppressed NFκB
activation in human KBM-5 chronic myeloid leukemia and A293
embryonic kidney carcinoma cells [25]. Garcinol, a polyisoprenylated
benzophenone, inhibited the activation of NFκB in human BxPC-3 and
Panc-1 pancreatic cancer cells [26] and squamous cell carcinoma of
the head and neck [27]. Lastly, a triterpene lupeol suppressed TPAinduced activation of NFκB in CD-1 mice [28].
More support for the mevalonate-inflammation connection is
drawn from studies with the statins, competitive inhibitors of HMG
CoA reductase, and protein prenyl transferase inhibitors showing their
parallel impacts on NFκB. Simvastatin inhibited NFκB activation in
human COLO 205 colon cancer cells [29], squamous cell carcinoma
SCC4 cells and KBM-5 cells [30]. Statins also suppressed the tumor
necrosis factor α- [31] and receptor activator of NFκB ligand (RANKL)
- [32] induced activation of NFκB in RAW 264.7 macrophages.
C-reactive protein-induced NFκB activation was inhibited by
simvastatin in human umbilical vein endothelial cells; reminiscent of
the findings by Ahn et al. with tocotrienols [15], mevalonate attenuated
the simvastatin effect on NFκB [33]. Consequent to Ras inactivation
[34], farnesyl transferase inhibitors FTI-276 and SCH 66336 suppressed
NFκB activation in rheumatoid arthritis synovial fibroblasts [35],
human Jurkat T-cell lymphoma cells, H1299 lung adenocarcinoma
cells, MCF-7 breast adenocarcinoma cells, and A293 embryonic kidney
cells [34].
By depleting mevalonate and consequently suppressing NFκB
activity, isoprenoids and most prominently tocotrienols may deliver
a “one-two punch” to inflammation. The omnipresence of the
mevalonate pathway and the critical role of inflammation in chronic
disorders suggest that dietary isoprenoids warrant further investigation
for their potential roles in the prevention and managing of chronic
diseases.
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